Why does tirzepatide make you burp?

Burping (eructation) is a named common adverse reaction on both the Mounjaro and Zepbound labels and shows up more often with tirzepatide than with semaglutide. It is likely a feature of the GIP arm of this dual GIP/GLP-1 agonist combined with slowed gastric emptying. In our community data 13% of users (754) reported it. It is almost always harmless; eating and drinking more slowly, easing off carbonated drinks, and avoiding swallowing air tend to help, and it usually settles as the dose stabilizes.

What tirzepatide side effects are serious or dangerous?

The rare-but-serious effects are gallbladder problems, severe hypoglycemia, and pancreatitis. In our community data these were reported by 1.8%, 0.9%, and 0.5% of users respectively. Tirzepatide also carries an FDA boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in people with medullary thyroid carcinoma or MEN 2. Severe, persistent abdominal pain is the key pancreatitis red flag and warrants emergency care.

When should I go to the ER on tirzepatide?

Seek urgent care for upper-right belly pain with fever or yellowing skin (possible gallbladder attack), severe persistent stomach pain that may radiate to the back (possible pancreatitis), or signs of severe low blood sugar such as confusion, shaking, sweating, or fainting (more likely if you also take insulin or a sulfonylurea). Do not try to manage these with hydration or meal timing.

Are tirzepatide side effects worse than semaglutide?

They are broadly similar GI profiles, with two differences worth knowing. Tirzepatide users report burping more often (a GIP-agonist quirk), while head-to-head trial data suggests overall GI tolerability is roughly comparable to or slightly better than semaglutide at equivalent effect. In our community data tirzepatide nausea (42%) and semaglutide nausea (44%) are close. Individual experience varies a lot by dose and titration speed.

Do Mounjaro and Zepbound have the same side effects as tirzepatide?

Yes — Mounjaro and Zepbound are both tirzepatide, so they share the same side-effect profile. The reported frequencies differ somewhat by dose and population: the weight-management doses (Zepbound) tend to report higher GI rates than lower diabetes doses of Mounjaro. The serious effects and the boxed warning apply to both.

Are the ProtocolPlus side-effect frequencies the same as official rates?

No — they are higher, and that is expected. Our nausea figure (42%) runs above the Mounjaro label (12 to 18% by dose) because our reporters skew toward higher weight-management doses and because self-reported tracking captures milder episodes a trial might not count. Our numbers are self-reported and un-adjudicated community data, illustrative until the live pipeline is wired — they are not validated clinical incidence and do not prove tirzepatide caused any individual effect.

A single unlabeled clear glass medication vial of colorless injectable solution beside a slim unbranded matte-grey single-dose auto-injector pen and a glass of water on a clean cool-grey clinical surface under soft studio lighting.

Tirzepatide Side Effects: What 5,800 Users Actually Report (2026)

Q: How long do tirzepatide side effects last?

The common GI effects are usually worst in the first day or two after a dose step-up and ease over the following one to two weeks as the body adapts. That is why tirzepatide is titrated slowly from 2.5 mg. Real-world reports put the median time to a reported GI event at around three to four weeks, fitting the early-escalation window. Persistent effects that do not settle, or that stop you holding down fluids, are a reason to contact your clinician rather than push through.

Prof. Joanna Trylska, Ph.D.Reviewed by Aurélie Rondon, Ph.D.

Updated 2026-06-17T00:00:00.000Z17 min read · 4,622 words

Most tirzepatide side effects are gastrointestinal and mild — nausea is the single most common, tied with the intended drop in appetite — and they tend to ease as the body adjusts; a small set of rare-but-serious effects (gallbladder problems, severe hypoglycemia, pancreatitis) is the part you actually need to watch for. This page answers the real tolerability question two ways at once: what 5,800 ProtocolPlus users report from real use, placed honestly next to the FDA-label and clinical-trial rates.

Most "tirzepatide side effects" pages give you one drug's label table. We do it differently. The headline below is first-party community data — what 5,800 ProtocolPlus users who tracked tirzepatide tolerability actually report — and we keep the trial and label rates clearly beside it as the validated benchmark. One thing to flag up front: tirzepatide is a dual GIP/GLP-1 agonist, and our reporters list burping (eructation) more often than semaglutide users do — a small but distinctive quirk of this molecule. For how tirzepatide itself works (mechanism, Mounjaro vs Zepbound, dosing), this page links up to the tirzepatide complete guide so it stays a clean safety-and-tolerability hub.

Key Takeaways

The honest top line (what our users report, N=5,800): the most common is nausea (42%, 2,436 users), tied with the intended effect — decreased appetite (42%, 2,436) — then diarrhea (33%), constipation (26%), and vomiting (20%). These are mostly mild-to-moderate and GI, and they cluster around dose increases.

A tirzepatide quirk: burping/eructation (13%, 754 users) shows up more often here than with semaglutide — it is on the Mounjaro and Zepbound labels as a common reaction and is generally harmless.

Common ≠ dangerous. The frequent effects are uncomfortable, not harmful for most people. The effects that matter for safety are the rare-but-serious ones: gallbladder problems (1.8%, 104 users), severe hypoglycemia (0.9%, 52), and pancreatitis (0.5%, 29).

The single most important safety action: treat severe, persistent abdominal pain (especially if it radiates to the back, with vomiting) as a pancreatitis red flag and go to the ER — do not "wait it out." (See the urgent-care block below.)

Self-report ≠ trial incidence ≠ causation. Our reported rates run a little higher than the Mounjaro diabetes label (e.g. our 42% nausea vs the label's 12–18% by dose) because our reporters skew toward higher weight-management doses — but our figures are un-adjudicated community reports, not validated incidence. Decreased appetite is the goal, not an adverse event.

A single unlabeled clear glass medication vial of colorless injectable solution beside a slim unbranded matte-grey single-dose auto-injector pen and a glass of water on a clean cool-grey clinical surface under soft studio lighting.

What are the most common tirzepatide side effects?

Across 5,800 ProtocolPlus users who tracked tirzepatide tolerability, the most-reported effects are gastrointestinal: nausea (42%), the intended decreased appetite (42%), diarrhea (33%), constipation (26%), and vomiting (20%) — almost all mild-to-moderate and worst right after a dose increase. This is a community-report ranking from our own app data, not a validated incidence table.

The pattern is exactly what tirzepatide's mechanism predicts. As a dual GIP/GLP-1 receptor agonist it slows how fast the stomach empties and turns down appetite, so digestive complaints and reduced hunger dominate the list. After the top GI cluster, reports tail off into milder, less specific effects: abdominal pain (18%, 1,044 users), fatigue (16%, 928), burping or eructation (13%, 754), heartburn or reflux (12%, 696), headache (11%, 638), injection-site reactions (11%, 638), dizziness (7%, 406), and hair thinning (6%, 348) — the last usually a consequence of rapid weight loss rather than the drug acting on hair directly.

That burping line is worth a pause. Belching is a named common adverse reaction on both the Mounjaro and Zepbound labels, and our community reports it more than semaglutide users do — a small signature of the GIP arm of this dual agonist. It is almost always harmless, just socially annoying. These shares come only from our community-reported dataset and describe what people experience and log, not trial-grade incidence and not causation. The mechanism behind each effect lives on the hub; for the molecule itself see the tirzepatide complete guide.

Citation capsule. Among 5,800 ProtocolPlus users who tracked tirzepatide tolerability, the most-reported effects were nausea (42%, 2,436 users), decreased appetite (42%, 2,436), diarrhea (33%, 1,914), constipation (26%, 1,508), and vomiting (20%, 1,160), with burping/eructation distinctively common at 13% (754). This is illustrative first-party data reflecting what the community reports — self-reported, not validated trial incidence, and not proof of causation. Source: ProtocolPlus app data (side-effects/tirzepatide.json), 2026, illustrative.

The moat: what 5,800 ProtocolPlus users report for tirzepatide, severity-colored. The frequent effects are mild-to-moderate and GI (with burping a tirzepatide signature); the three red bars are the rare-but-serious ones to know. Illustrative app data — a report signal, not validated incidence.

When should you seek urgent care on tirzepatide?

Go to urgent care or the ER if you have severe, persistent stomach pain (possible pancreatitis), pain in the upper-right belly with fever or yellowing skin (possible gallbladder attack), or signs of severe low blood sugar like confusion, shaking, sweating, or fainting. These three are rare — together under ~3.5% of our reporters — but they are the effects that turn a tolerability issue into an emergency, so they come before everything else.

These are not the everyday nausea-and-titration effects. They are the small-but-serious tail of the distribution, and each has a clear warning sign and a clear action. Do not try to manage them with hydration or meal timing — they need a clinician.

⚠ WHEN TO SEEK URGENT CARE — the three red flags

Gallbladder problems

1.8% of our reporters (104)

Warning sign: pain in the upper-right belly, fever, nausea, or yellowing of the skin or eyes (jaundice). Rapid weight loss raises gallstone risk.

Action: seek urgent care the same day.

Severe hypoglycemia

0.9% of our reporters (52)

Warning sign: shaking, sweating, confusion, blurred vision, or fainting — mainly when combined with insulin or a sulfonylurea.

Action: take fast sugar now; get emergency help if confused or unable to swallow.

Pancreatitis

0.5% of our reporters (29)

Warning sign: severe, persistent upper-abdominal pain, often radiating to the back, usually with vomiting.

Action: stop the drug and go to the ER. Do not wait it out.

Also note the FDA boxed warning: in rodents tirzepatide caused dose- and duration-dependent thyroid C-cell tumors; it is contraindicated if you or a close relative has medullary thyroid carcinoma (MTC) or MEN 2. A persistent neck lump, hoarseness, or trouble swallowing warrants a clinician check.

Citation capsule. Tirzepatide's serious risks per its FDA labels (Mounjaro and Zepbound) include acute gallbladder disease (cholelithiasis 1.1%, cholecystitis 0.7% vs placebo in the weight-management pool), acute pancreatitis (discontinue if suspected; adjudicated ~0.23 vs 0.11 events per 100 patient-years), and increased hypoglycemia risk when combined with insulin or a sulfonylurea; it carries a boxed warning for rodent thyroid C-cell tumors and is contraindicated in MTC/MEN 2. Source: FDA Mounjaro (215866) & Zepbound (217806) Prescribing Information, 2024–2026.

What do the common tirzepatide side effects feel like, and how do people manage them?

The common effects are gastrointestinal, mostly mild-to-moderate, tend to peak in the days after a dose increase, and ease over the following weeks as the body adapts — which is exactly why tirzepatide is titrated up slowly from 2.5 mg. Below is each frequent effect: what it feels like, why it happens, when it tends to start and ease, and how our community manages it. These are descriptions of common practice, not a prescription — dose changes belong with your clinician (see the tirzepatide dosage calculator for how titration is structured).

Nausea (42%, 2,436 users)

The most common complaint, and usually the one people worry about most before starting. It comes from delayed gastric emptying — food sits longer, so the stomach feels full and queasy. It is typically worst in the first day or two after a dose step-up and fades over the following one to two weeks. Community practice leans on smaller, more frequent meals, stopping eating at the first sign of fullness, avoiding greasy or very large meals, staying hydrated, and not rushing the next dose increase.

Decreased appetite (42%, 2,436 users)

Worth a special note: for most users this is the intended effect, not an adverse one — it is how the drug produces weight loss, and on tirzepatide it is often described as especially strong. We track it because it occasionally becomes excessive, with people skipping meals entirely or under-eating to the point of fatigue, dizziness, or dehydration. The community workaround is protein-forward meals on a schedule (eating by the clock rather than by hunger) so intake stays adequate even when appetite is low.

Diarrhea and constipation (33% and 26%)

Tirzepatide can push gut motility in either direction. Diarrhea (1,914 users) tends to be transient around dose changes; constipation (1,508) is more often a slow build tied to eating and drinking less. There is a quirk worth knowing: in the Zepbound trials, constipation was actually highest at the lowest 5 mg dose and eased at higher doses, the opposite of how nausea behaves — so the two effects do not track together. Community practice is straightforward: fluids and fiber for constipation, bland low-residue foods and electrolytes for diarrhea, and watching for dehydration when either is severe or persistent.

Vomiting (20%, 1,160 users)

Less common than nausea and usually linked to a too-fast titration or a large/greasy meal. The reason it earns a "moderate" tag is that persistent vomiting risks dehydration and, in turn, kidney strain. Occasional vomiting is generally managed like nausea; vomiting that keeps you from holding down fluids is a reason to call a clinician, not to push through.

Burping / eructation (13%, 754 users) — the tirzepatide signature

This is the effect that most distinguishes tirzepatide from semaglutide in our data. Belching shows up as a named common reaction on both the Mounjaro and Zepbound labels, and our reporters list it more than semaglutide users do — likely a feature of the GIP arm of this dual agonist combined with slowed gastric emptying. It is almost always harmless, just socially awkward. Community practice is simple: eat and drink more slowly, go easy on carbonated drinks, and avoid swallowing air by talking while eating; it tends to settle as the dose stabilizes.

The milder tail (abdominal pain, fatigue, reflux, headache, injection-site, dizziness, hair thinning)

Abdominal pain (18%) is usually mild and gas-related — but remember the red flag: severe, persistent, radiating pain is the pancreatitis signal, not ordinary cramping. Fatigue (16%) and headache (11%) often track with eating and drinking less early on and tend to settle. Heartburn/reflux (12%), injection-site reactions (11%), and dizziness (7%) are typically minor. Hair thinning (6%) is usually a rapid-weight-loss effect (telogen effluvium), not the drug acting on hair directly, and tends to recover as weight stabilizes.

When do the side effects start and ease? (the time-course)

The reason "go slow" works is that the side-effect curve is tied directly to the dose-escalation schedule, not to a fixed calendar date. Tirzepatide is started at 2.5 mg and stepped up every four weeks specifically to keep the GI effects tolerable, and the label's overall GI rate climbs with dose — about 37% at 5 mg up to roughly 44% at 15 mg in the Mounjaro program. In practice, the pattern most people describe is a small flare in the first day or two after each dose increase, then a settle over the next one to two weeks as the body adapts — followed by a fresh, usually milder flare at the next step-up. Real-world pharmacovigilance reports put the median time to a reported GI event at around three to four weeks, which fits the early-escalation window. By the time someone reaches and holds their maintenance dose, the day-to-day nausea has typically faded for most users, which is why tolerability complaints are heaviest during titration and lighter on maintenance. This is also the practical argument for not skipping ahead: a held or repeated dose step is the standard way clinicians smooth a rough escalation.

A person's hands resting a glass of water on a light wooden kitchen table next to plain crackers and ginger tea in soft morning light, suggesting calm management of mild nausea.

Our take: The single biggest lever on tolerability is titration speed. Almost every common effect on this page is dose-step-related and eases with time, so the community pattern that works is "go slow, hold a dose longer if you need to, and don't chase the next increase." Comfort beats speed.

How does our community report compare to the trial and label rates?

Our community-reported frequencies run noticeably higher than the Mounjaro diabetes label — our nausea (42%) versus the label's 12% to 18% depending on dose — mainly because our reporters skew toward the higher weight-management doses and because self-reported tracking captures milder episodes a trial might not count; read the gap as a difference in method and population, not as proof the drug is worse than the label says. The honest framing matters here: community self-report, controlled-trial incidence, and population real-world rates are three different things, and none of them establishes that tirzepatide caused any single person's effect.

Two more honesty points sit on top of the comparison. First, decreased appetite is largely the intended effect — it appears in trials too (around 5% to 11% by dose on the Mounjaro label), but counting it as a "side effect" overstates the harm side of the ledger, so we flag it rather than rank it as an adverse event. Second, the trial data shows a clean dose-dependence: Mounjaro nausea runs 12% at 5 mg, 15% at 10 mg, and 18% at 15 mg, while the Zepbound weight-management doses report higher still (nausea around 25% to 27% across 5–15 mg). So our 42% community average is best read alongside the fact that our users skew toward weight-loss dosing, where rates are highest — a single community number hides a real dose gradient.

There is also a discontinuation point worth keeping in proportion. Despite high nausea rates, most people who feel queasy ride it out: GI-related discontinuation on the Mounjaro label ran from 3.0% at 5 mg up to 6.6% at 15 mg, and on Zepbound from 1.9% up to 4.3%. (You may see a "25% discontinued at 15 mg" figure online — that is all-cause discontinuation from a SURPASS comparison, not GI-only, so do not conflate the two.) For the rare-but-serious tail, the validated label rates are reassuringly small: cholelithiasis around 1.1%, cholecystitis 0.7%, and adjudicated pancreatitis at roughly 0.23 events per 100 patient-years.

The table below places our community report next to the validated benchmarks for the GI effects where the comparison is clean.

Effect	ProtocolPlus community (N=5,800)	Mounjaro label (5→15 mg)	Zepbound label (5→15 mg)	Read it as
Nausea	42% (2,436)	12–18%	~25–27%	Community higher — dose & method
Diarrhea	33% (1,914)	12–17%	19–23%	Community higher
Vomiting	20% (1,160)	5–9%	8–13%	Community higher
Constipation	26% (1,508)	6–7%	11–17%*	Community higher (*highest at low dose)
Burping / eructation	13% (754)	named common AE	4–6%	Tirzepatide signature; community higher
Decreased appetite	42% (2,436)	5–11% (intended)	(mechanism)	The goal, not an adverse event
Gallbladder	1.8% (104)	—	1.1% cholelithiasis	Rare; matches label signal

The honesty visual: our community self-report runs higher than both labels' top-dose GI rates — partly because our reporters skew toward higher weight-management doses and self-report captures milder episodes. Self-report is not validated incidence, and none of it proves causation.

Why does tirzepatide cause these side effects?

Almost every common tirzepatide side effect traces back to one mechanism: as a dual GIP/GLP-1 receptor agonist it slows gastric emptying and acts on appetite and nausea centers, so the body's first responses are digestive — fullness, nausea, burping, altered bowel habits — and reduced hunger. That single cause is also why the effects are dose-related and why slow titration tames them. The GIP component is part of why belching shows up more than with a GLP-1-only drug. The deep mechanism lives on the hub; this is the short version that explains the pattern above.

The serious effects have separate, more specific causes. Gallbladder problems are driven largely by rapid weight loss itself (fast fat loss raises gallstone risk), not a direct toxic effect. Hypoglycemia is not usually caused by tirzepatide alone — it appears mainly when the drug is stacked with insulin or a sulfonylurea, which is why those combinations need dose adjustment. Pancreatitis is a rare reaction flagged on the label. And the thyroid C-cell boxed warning comes from rodent studies; whether it translates to humans is unknown, which is why the contraindication is precautionary. For the full receptor-level science, brands, and dosing, see the tirzepatide complete guide.

Citation capsule. Tirzepatide is a dual GIP/GLP-1 receptor agonist that slows gastric emptying and reduces appetite, which accounts for the dose-related gastrointestinal effects (including the distinctively common belching). Gallbladder events are associated with rapid weight loss; hypoglycemia risk rises mainly with concomitant insulin or sulfonylureas; the thyroid C-cell boxed warning derives from rodent data of unknown human relevance. Source: FDA Mounjaro/Zepbound Prescribing Information, 2024–2026.

Who should be cautious, and who should avoid tirzepatide?

Tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, and it is used with extra caution in people with a history of pancreatitis, gallbladder disease, severe GI conditions, diabetic retinopathy, or those taking insulin or a sulfonylurea. It is also not used in pregnancy, and it can reduce the effectiveness of oral birth control around dose changes. These are the hard lines; everything else is a conversation with a clinician about your specific history.

A few practical cautions follow from the side-effect profile. People prone to dehydration — older adults, anyone with kidney concerns — should be especially careful with persistent vomiting or diarrhea, since dehydration is the usual path to kidney strain on this drug. Anyone combining tirzepatide with other glucose-lowering medication needs those doses reviewed to avoid hypoglycemia. And because the research-grade ("for research use only") versions of tirzepatide are unregulated for human use, they add quality and dosing uncertainty on top of the drug's own profile; for how to think about that, see how to vet peptide quality. If you are weighing tirzepatide against semaglutide on tolerability, the semaglutide side effects page runs the same community-data lens. None of this page replaces that clinician conversation.

Frequently Asked Questions

The most common are gastrointestinal. Among 5,800 ProtocolPlus users who tracked tolerability, the most-reported effects were nausea (42%), decreased appetite (42%, which is largely the intended effect), diarrhea (33%), constipation (26%), and vomiting (20%), with burping/eructation distinctively common at 13%. These are mostly mild-to-moderate, cluster around dose increases, and tend to ease over a week or two. This is illustrative self-reported community data, not validated trial incidence.

The bottom line

If you came here worried about tirzepatide side effects, the honest answer is layered. The effects you will most likely feel are gastrointestinal and mild-to-moderate — nausea leads, tied with the intended drop in appetite, with burping a distinctive tirzepatide extra — and they mostly ease with slow titration and a few practical habits. Our community's frequencies run higher than the Mounjaro and Zepbound labels, but that reflects higher weight-management dosing and self-report capturing milder episodes, not a hidden danger.

The effects you actually need to watch are the rare-but-serious tail: gallbladder problems, severe hypoglycemia, and pancreatitis — under ~3.5% of reporters combined, but each with a clear warning sign and a clear action to go get help. Treat severe, persistent abdominal pain as the line that ends self-management. From here, the natural next reads are the tirzepatide complete guide for the molecule and brands, the tirzepatide dosage calculator for how titration is structured, semaglutide side effects if you are comparing the two, and best peptides for weight loss for the wider landscape.

Sources

U.S. Food & Drug Administration. "Mounjaro (tirzepatide) injection — Prescribing Information" (Section 6, Adverse Reactions; Boxed Warning; Warnings & Precautions). Application 215866, 2025 revision. Retrieved 2026-06-17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
U.S. Food & Drug Administration. "Zepbound (tirzepatide) injection — Prescribing Information" (Section 6, Adverse Reactions; Boxed Warning). Application 217806, 2026 revision. Retrieved 2026-06-17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
Eli Lilly Medical Information. "Common adverse events with Mounjaro (tirzepatide) — per-dose rates" (mirrors the SURPASS-program label table). Retrieved 2026-06-17. https://medical.lilly.com/us/products/answers/what-are-the-common-adverse-events-with-mounjaro-tirzepatide-in-adults-310838
Eli Lilly Medical Information. "Gastrointestinal adverse events reported in Zepbound (tirzepatide) clinical studies — per-dose rates" (SURMOUNT program). Retrieved 2026-06-17. https://medical.lilly.com/us/products/answers/how-often-were-gastrointestinal-adverse-events-reported-in-zepbound-tirzepatide-clinical-studies-206711
Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205-216. DOI 10.1056/NEJMoa2206038. Retrieved 2026-06-17. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Lin Y, et al. "Tirzepatide-Induced Gastrointestinal Manifestations: a systematic review and meta-analysis." PMC, 2023. PMID/PMC10614464. Retrieved 2026-06-17. https://pmc.ncbi.nlm.nih.gov/articles/PMC10614464/
"Real-World Safety of Tirzepatide: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS), 2022–2025." PMC 12469573. Retrieved 2026-06-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469573/ (FAERS = spontaneous-report disproportionality signals, not incidence)
ProtocolPlus. "Community-reported tolerability data: tirzepatide" (side-effects/tirzepatide.json). Illustrative first-party app data, 2026. N = 5,800 users who tracked tirzepatide tolerability. Self-reported community frequency, not validated incidence and not proof of causation.